This information is intended for Colorado Prescribers
HB 19-1131
MARKETED PRESCRIPTION DRUG |
COLORADO WAC DISCLOSURE FORM |
DATE UPDATED |
---|---|---|
Sanofi Singular Form with QR Code |
1/6/2023 | |
Diabetes Products |
1/4/2023 |
|
Vaccines |
8/31/2023 | |
ALDURAZYME® (laronidase) |
1/16/2023 |
|
ALPROLIX® [Coagulation factor IX (recombinant), Fc fusion protein] |
1/4/2023 | |
ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] |
3/27/2023 | |
AUBAGIO® (teriflunomide) |
7/3/2023 | |
CABLIVI® (caplacizumab-yhdp) |
1/4/2023 | |
CERDELGA® (eliglustat) capsules, for oral use |
1/16/2023 |
|
Cerezyme® (imiglucerase) for injection |
1/19/2022 |
|
DUPIXENT® (dupilumab) Injection |
1/4/2023 | |
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] |
1/4/2023 | |
ENJAYMO® (sutimlimab-jome) injection, for intravenous use |
1/4/2023 | |
FABRAZYME® (agalsidase beta) for injection, for intravenous use |
1/16/2023 |
|
JEVTANA® (cabazitaxel) Injection |
7/3/2023 | |
KEVZARA® (sarilumab) |
1/4/2023 | |
LEMTRADA® (alemtuzumab) |
7/3/2023 | |
LOVENOX® (enoxaparin sodium injection) |
7/15/2022 |
|
LUMIZYME® (alglucosidase alfa) |
1/16/2023 |
|
Mozobil® (plerixafor injection) |
1/4/2023 | |
MULTAQ® (dronedarone) |
1/4/2023 | |
NEXVIAZYME® (avalglucosidase alfa-ngpt) for injection, for intravenous use |
1/16/2023 |
|
REZUROCK® (belumosudil) tablets |
1/4/2023 | |
SARCLISA® (isatuximab-irfc) injection |
7/3/2023 | |
Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] |
1/4/2023 | |
THYROGEN® (thyrotropin alfa for injection) |
1/18/2023 |
|
XENPOZYME® (olipudase alfa-rpcp) for injection, for intravenous use |
8/16/2023 |
House Bill 19-1131. Published by the General Assembly of the State of Colorado
Please See Full Prescribing Information, including Boxed Warning, for Aldurazyme, Aubagio, Jevtana, Kevzara, Lemtrada, Lovenox, Lumizyme, Multaq,
Nexviazyme, Thymoglobulin , Xenpozyme
MAT-US-2007971-v9.0-07/2023